Lysophosphatidic acid and renal fibrosis.
The development of fibrosis involves a multitude of events and molecules. Until now the majority of these molecules were found to be proteins or peptides. But recent data show significant involvement of the phospholipid lysophosphatidic acid (LPA) in the development of pulmonary, liver and renal fibrosis. The latest data on the role of LPA and the G-protein-coupled LPA1 receptor in the development of renal fibrosis will be discussed. LPA1-receptor activation was found to be associated with increased vascular leakage and increased fibroblast recruitment in pulmonary fibrosis. Furthermore, in renal fibrosis LPA1-receptor activation stimulates macrophage recruitment and connective tissue growth factor expression. The observations make this receptor an interesting alternative and new therapeutic target in fibrotic diseases.
Pradère
Jean-Philippe
JP
Inserm, U858/I2MR, Department of Metabolism and Obesity, Team #3, 1 Avenue Jean Poulhès, BP 84225, 31432 Toulouse Cedex 4, France.
Gonzalez
Julien
J
Klein
Julie
J
Valet
Philippe
P
Grès
Sandra
S
Salant
David
D
Bascands
Jean-Loup
JL
Saulnier-Blache
Jean-Sébastien
JS
Schanstra
Joost P
JP
D000818:Animals; D005355:Fibrosis / Q000378:metabolism; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism* / Q000503:physiopathology; D008246:Lysophospholipids / Q000378:metabolism*; D008954:Models, Biological; D049368:Receptors, Lysophosphatidic Acid / Q000378:metabolism
D008246:Lysophospholipids; D049368:Receptors, Lysophosphatidic Acid; C032881:lysophosphatidic acid